Ken Griffin Atea Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,800 shares of AVIR stock, worth $9,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,800

Previous 13,100 78.63%

Holding current value

$9,324

Previous $52,000 82.69%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $4.04 $1.09 Million - $1.33 Million	329,603 Added 168.16%	525,603 $1.74 Million
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $71,026 - $104,816	22,986 Added 13.29%	196,000 $791,000
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.35 $1.15 Million - $1.38 Million	-411,674 Reduced 70.41%	173,014 $527,000
Q3 2023 Nov 14, 2023	SELL	$3.0 - $3.79 $2.69 Million - $3.4 Million	-897,095 Reduced 60.54%	584,688 $1.75 Million
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $320,759 - $505,620	-99,925 Reduced 6.32%	1,481,783 $5.54 Million
Q1 2023 May 15, 2023	BUY	$3.0 - $4.97 $2.93 Million - $4.85 Million	975,523 Added 160.93%	1,581,708 $5.3 Million
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $1.36 Million - $1.93 Million	313,381 Added 107.03%	606,185 $2.92 Million
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $185,287 - $296,662	33,750 Added 13.03%	292,804 $1.67 Million
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $6.9 Million - $10.6 Million	-1,295,171 Reduced 83.33%	259,054 $1.84 Million
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $630,888 - $1.05 Million	-114,707 Reduced 6.87%	1,554,225 $11.2 Million
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $12 Million - $70 Million	1,569,450 Added 1577.62%	1,668,932 $14.9 Million
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $895,881 - $1.47 Million	42,001 Added 73.07%	99,482 $3.49 Million
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $1.03 Million - $3.16 Million	53,467 Added 1332.01%	57,481 $1.23 Million
Q1 2021 May 17, 2021	SELL	$41.42 - $88.44 $6.8 Million - $14.5 Million	-164,191 Reduced 97.61%	4,014 $248,000
Q4 2020 Feb 16, 2021	BUY	$26.36 - $41.78 $4.43 Million - $7.03 Million	168,205 New	168,205 $7.03 Million

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.1M

Call Options Held

71.8K

Put Options Held

318K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $277M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account